Drug intelligence / Profile preview

Ad5-PA

Development stage: Preclinical
Lead developer: Introgen Therapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intratumoral

Overview

Ad5-PA is a recombinant adenovirus-5 vector that serves as a control in gene therapy studies. It is engineered to contain a poly-adenosine sequence but lacks a therapeutic transgene, such as the wild-type p53 gene. Its primary function is to enable researchers to differentiate the effects of the viral vector delivery system from the effects of the specific therapeutic gene being investigated. It was used in studies involving prostate cancer cells.

Targets

TLR9 (Toll-like receptor 9)αVβ5 (Integrin αVβ5)F10 (Factor Xa)C4BPB (Complement component 4 binding protein beta chain)CXADR (Coxsackievirus and adenovirus receptor)TP53 (Cellular Tumor Antigen p53 R175H)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Ad5-PA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad5-PA.

Explore the full profile